{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:46:53Z","timestamp":1791827213905,"version":"4.3.4"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"DOI":"10.1007\/s10654-026-01478-z","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:07:05Z","timestamp":1791824825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to the letter to the editor by J. Aarstad"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3310-0329","authenticated-orcid":false,"given":"Isabel A. L.","family":"Slurink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J. M.","family":"Bonten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam C. J. M.","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia C. J. L.","family":"Bruijning-Verhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"1478_CR1","unstructured":"Aarstad J. Can we rule out that COVID-19 vaccination did increase all-cause mortality? Eur J Epidemiol, 2026."},{"key":"1478_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-025-01334-6","author":"IA Slurink","year":"2026","unstructured":"Slurink IA, et al. COVID-19 vaccination and short-term mortality risk: a nationwide self-controlled case series study in The Netherlands. Eur J Epidemiol. 2026. https:\/\/doi.org\/10.1007\/s10654-025-01334-6.","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"1478_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36494-0","volume":"14","author":"V Nafilyan","year":"2023","unstructured":"Nafilyan V, et al. Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England. Nat Commun. 2023;14(1):1541.","journal-title":"Nat Commun"},{"issue":"1","key":"1478_CR4","doi-asserted-by":"publisher","first-page":"e0281296","DOI":"10.1371\/journal.pone.0281296","volume":"18","author":"M-J Kim","year":"2023","unstructured":"Kim M-J, et al. 10-year survival outcome after clinically suspected acute myocarditis in adults: A nationwide study in the pre-COVID-19 era. PLoS ONE. 2023;18(1):e0281296.","journal-title":"PLoS ONE"},{"key":"1478_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.12688\/f1000research.160980.5","volume":"14","author":"J Aarstad","year":"2026","unstructured":"Aarstad J. Mortality involving and not involving COVID-19 among vaccinated vs. unvaccinated in England between Apr 21 and May 23. F1000Research. 2026;14:133.","journal-title":"F1000Research"},{"key":"1478_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.12688\/f1000research.177279.1","volume":"15","author":"J Aarstad","year":"2026","unstructured":"Aarstad J. Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic\u2019s aftermath: A population-level study of over 3,000 US counties with over 320 million people. F1000Research. 2026;15:244.","journal-title":"F1000Research"}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-026-01478-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10654-026-01478-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-026-01478-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:07:05Z","timestamp":1791824825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10654-026-01478-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":6,"alternative-id":["1478"],"URL":"https:\/\/doi.org\/10.1007\/s10654-026-01478-z","relation":{},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"value":"0393-2990","type":"print"},{"value":"1573-7284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"3 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MB has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU and\/or Ecraid received funding for study collaboration from AstraZeneca, Sanofi, Janssen, Pfizer, MSD, Novavax, Sequiris and GSK. UMCU and\/or Ecraid received funding as part of the public private partnership IMI-funded COMBACTE-NET, COMBACTE-CARE, COMBACTE-MAGNET, VITAL and PriMaVeRA. MS is head of a department that conducts studies for the European Medicines Agency, the European Commission, and medicine manufacturers, all according to the ENCePP code of conduct. MS does not hold personal financial relationships with the companies. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as the study did not analyze data.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as the study did not analyze data.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as the study did not analyze data.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}